Clinical and Molecular Hepatology

The most appropriate treatment for acute gastric variceal bleeding (GVB) is currently endoscopic gastric variceal obturation (GVO) using Histoacryl®. However, the secondary prophylactic efficacy of beta-blocker (BB) after GVO for the first acute episode of GVB has not yet been established. The secondary prophylactic efficacy of BB after GVO for the first acute episode of GVB was evaluated in this study.

Methods

Ninety-three patients at Soonchunhyang University Hospital with acute GVB who received GVO using Histoacryl® were enrolled between June 2001 and March 2010. Among these, 42 patients underwent GVO alone (GVO group) and 51 patients underwent GVO with adjuvant BB therapy (GVO+BB group). This study was intended for patients in whom a desired heart rate was reached. The rates of rebleeding-free survival and overall survival were calculated for the two study groups using Kaplan-Meyer analysis and Cox's proportional-hazards model.

Results

The follow-up period after the initial eradication of gastric varices was 18.14±25.22 months (mean±SD). During the follow-up period, rebleeding occurred in 10 (23.8%) and 21 (41.2%) GVO and GVO+BB patients, respectively, and 39 patients died [23 (54.8%) in the GVO group and 16 (31.4%) in the GVO+BB group]. The mean rebleeding-free survival time did not differ significantly between the GVO and GVO+BB groups (65.40 and 37.40 months, respectively; P=0.774), whereas the mean overall survival time did differ (52.54 and 72.65 months, respectively; P=0.036).

Conclusions

Adjuvant BB therapy after GVO using Histoacryl® for the first acute episode of GVB could decrease the mortality rate relative to GVO alone. However, adjuvant BB therapy afforded no benefit for the secondary prevention of rebleeding in GV.

Citations

Citations to this article as recorded by

A randomized controlled trial comparing large-volume band ligator and cyanoacrylate injection in the endoscopic management of actively bleeding gastric varices
Ding Shi, Guojing Xu, Weijin Pan
Scientific Reports.2025;[Epub] CrossRef
Risk Factors for Rebleeding After Endoscopic Injection of Cyanoacrylate Glue for Gastric Varices: A Systematic Review and Meta-Analysis
Yihuan Hu, Mei Zhou, Deliang Liu, Jian Gong
Digestive Diseases and Sciences.2024; 69(8): 2890. CrossRef
Liver stiffness-spleen diameter to platelet ratio score (LSPS model) predicts variceal rebleeding for cirrhotic patients
Xixuan Wang, Hao Han, Jian Yang, Yang Cheng, Xiaochun Yin, Lihong Gu, Jiangqiang Xiao, Yi Wang, Xiaoping Zou, Lei Wang, Ming Zhang, Yuzheng Zhuge, Feng Zhang
European Journal of Gastroenterology & Hepatology.2023; 35(4): 488. CrossRef
Balloon-occluded retrograde transvenous obliteration and simultaneous endoscopic cyanoacrylate injection for treating gastric varices draining through gastrorenal shunts
Jindong Chu, Zheng Lu, Chunsheng Chi, Wenhui Zhang, Qian Bi, Xuemei Ma, Lijun Shen, Qin Wu, Yanling Wang, Jingjing Han, Xiaoli Yu, Bo Jin
Arab Journal of Gastroenterology.2023; 24(4): 218. CrossRef
The efficacy and safety of beta-blockers versus cyanoacrylate injection for gastric variceal bleeding
Yubao Sun, Sheng Li, Feng Li
Medicine.2021; 100(21): e26039. CrossRef
Endoscopic Cyanoacrylate Glue Injection in Management of Gastric Variceal Bleeding: US Tertiary Care Center Experience
Subhash Chandra, Adrian Holm, Rami G. El Abiad, Henning Gerke
Journal of Clinical and Experimental Hepatology.2018; 8(2): 181. CrossRef
Management of gastric varices
Delphine Weil, Jean-Paul Cervoni, Nadim Fares, Marika Rudler, Christophe Bureau, Aurélie Plessier, Thong Dao, Arnaud Pauwels, Dominique Thabut, Paul Castellani, Frederic Oberti, Nicolas Carbonell, Laure Elkrief, Vincent Di Martino, Thierry Thevenot
European Journal of Gastroenterology & Hepatology.2016; 28(5): 576. CrossRef

10,110 View
61 Download
Crossref

The Korean Journal of Prevention of Variceal Bleeding and Measurement of Hepatic Vein Pressure Gradient: Kwang Hee Youn , Dong Joon Kim; Korean J Hepatol 2006;12(3):464-468.

Abstract
PDF

Objective

s: A reduction in hepatic venous pressure gradient (HVPG) of ≥20% of baseline or to ≤12 mmHg (responders) is associated with a reduced risk of first variceal bleeding. The aim of this study was to evaluate whether this protective effect is maintained in the long term and if it extends to other portal hypertension complications. Methods: Seventyone cirrhotic patients with esophageal varices and without previous variceal bleeding who entered into a program of prophylactic pharmacological therapy and were followed for up to 8 yr were evaluated. All had two separate HVPG measurements, at baseline and after pharmacological therapy with propranolol± isosorbide mononitrate. Results: Forty-six patients were nonresponders and 25 were responders. Eightyear cumulative probability of being free of first variceal bleeding was higher in responders than in nonresponders (90% vs 45%, p=0.026). The lack of hemodynamic response and low platelet count were the only independent predictors of first variceal bleeding. Additionally, reduction of HVPG was independently associated with a decreased risk of spontaneous bacterial peritonitis (SBP) or bacteremia. No significant differences in the development of ascites, hepatic encephalopathy, or survival were observed. Conclusions: The hemodynamic response in cirrhotic patients is associated with a sustained reduction in the risk of first variceal bleeding over a long-term follow-up. Reduction of HVPG also correlate with a reduced risk of SBP or bacteremia. [Abstract reproduced by permisson of Am J Gastroenterol 2006;101:506-512]